Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy

Menopause

Volumn 12, Issue 6, 2005, Pages 699-707

  Ödmark, Inga Stina ^a   Bixo, Marie ^a   Englund, Doris ^b   Risberg, Björn ^c   Jonsson, Björn ^d   Olsson, Sven Eric ^e  

^a UMEÅ UNIVERSITY   (Sweden)

^b Department of Women's and Children's Health   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UPPSALA UNIVERSITY   (Sweden)

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

Bleeding pattern; Endometrial biopsy; Endometrial safety; Hormone therapy; Long cycle

Indexed keywords

AMENORRHEA; ARTICLE; BIOPSY; BLEEDING; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; FEMALE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; ULTRASOUND; UTERINE BLEEDING PATTERN;

BIOPSY; BLOOD PRESSURE; BODY MASS INDEX; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MEDROXYPROGESTERONE ACETATE; MULTIVARIATE ANALYSIS; PATIENT DROPOUTS; POSTMENOPAUSE; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 27944498203     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000185119.74706.7b     Document Type: Article

References (36)

1. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes [Cochrane Review]. Cochrane Library, Issue 2. Oxford: Update Software 2001.
2. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000;(2):CD000402.
3. Sturdee DW, Wade-Evans T, Paterson MEL, Thom M, Studd JWW. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. BMJ 1978;1:1575-1577.
4. Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effect of various types and dosage of progestogens on the postmenopausal endometrium. J Reprod Med 1982;27:539-548.
5. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:336-343.
6. Hammarbäck S, Bäckström T, Holst J, et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 1985;64:393-397.
7. Björn I, Bixo M, Strandberg-Nöjd K, et al. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000;183:1419-1426.
8. Chlebowski R, Hendrix S, Langer R, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003;289:3243-3253.
9. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992;15:151-158.
10. Ricardo GH. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161:1854-1858.
11. Björn I, Bäckström T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86.
12. Sturdee DW. Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Int J Fertil 1996;41:22-28.
13. Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995;21:39-44.
14. Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693-700.
15. Erkkola R, Kumento U, Lehmuskoski S, Mattila L, Mustonen M. No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years. J Br Menopause Soc 2004;10:9-13.
16. Pinto AB, Binder EF, Kohrt WM, Bronder DR, Williams DB. Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot study. Am J Obstet Gynecol 2003;189:11-15.
17. Arne V. Gestagen as additions to estrogen treatment in the menopause. Swedish Med Products Agency Rep 2000;1:113-121.
18. Ödmark I-S, Jonsson B, Bäckström T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17β-estradiol and norethindrone acetate. Am J Obstet Gynecol 2001;184:1131-1138.
19. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;280:1510-1517.
20. Mazur TM, Kurman MT. Diagnosis of Endometrial Biopsies and Curettings: A Practical Approach. New York: Springer-Verlag, 1995.
21. Fleischer AC, Kalemeris GC, Entman SS. Sonographic depiction of the endometrium during normal cycles. Ultrasound Med Biol 1986;12:271-277.
22. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-1223.
23. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-131.
24. David A, Reif A, Weissglas L. Cyclic and combined hormonal treatment regimen in postmenopausal women: Hysteroscopic findings. In: Fioretti P, et al., eds. Postmenopausal Hormonal Therapy: Benefits and Risks. New York, NY: Raven Press, 1987.
25. The Writing Group for PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.
26. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-251.
27. Williams DB, Voigt BJ, Fu YS, Schonenfeld MJ, Judd HL. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol 1994;84:787-793.
28. Bjarnason K, Cerin Å, Lindgren R, Weber T. The Scandinavian Long Cycle Study Group. Adverse endometrial effects of long cycle hormone replacement therapy. Maturitas 1999;32:161-170.
29. Pettersson F, Björkholm E. Incidence and mortality trends for female genital tumors in Sweden 1958-1994: a review based on the Swedish Cancer Registry and the Cause of Death Registry. Paper presented at the IGCS Meeting, Fukuoka, Japan, October 20-24, 1997.
30. Björn I, Bixo M, Strandberg-Nöjd K, et al. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol Endocrinol 2002;16:1-8.
31. Olssson H, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-1392.
32. Rossouw JE. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
33. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
34. Ettinger B, Li D-K, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril 1998;69:865-869.
35. Al-Azzawi F. Management of the menopause. In: Al-Azzawi F, Wahab M, ed. Hormone Replacement Therapy and the Endometrium. New York, NY: Parthenon Publishing Group Limited, 2001:153.
36. Limouzin-Lamothe M-A. What women want from hormone replacement therapy: results of an international survey. Eur Obstet Gynecol 1996;64(Suppl 1):21-24.